Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1984 1
1985 1
1986 2
1987 1
1990 1
1993 1
1994 1
1995 4
1996 1
1997 3
1998 3
2000 3
2001 3
2002 5
2003 8
2004 7
2005 6
2006 8
2007 5
2008 8
2009 7
2010 18
2011 14
2012 8
2013 16
2014 15
2015 5
2016 11
2017 11
2018 10
2019 12
2020 14
2021 9
2022 5
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Lung Squamous Cell Carcinoma, Small Cell Variant"
Page 1
The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification.
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I; WHO Panel. Travis WD, et al. J Thorac Oncol. 2015 Sep;10(9):1243-1260. doi: 10.1097/JTO.0000000000000630. J Thorac Oncol. 2015. PMID: 26291008 Free article.
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with numerous important changes from the 2004 WHO classification. The most significant changes in this edition involve (1) use of immunohistochem …
The 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart has just been published with …
Bidirectional Association Between Cardiovascular Disease and Lung Cancer in a Prospective Cohort Study.
Zhang S, Liu L, Shi S, He H, Shen Q, Wang H, Qin S, Chang J, Zhong R. Zhang S, et al. J Thorac Oncol. 2024 Jan;19(1):80-93. doi: 10.1016/j.jtho.2023.09.004. Epub 2023 Sep 12. J Thorac Oncol. 2024. PMID: 37703998
Besides, polygenic risk scores were estimated by integrating genome-wide association studies identified risk variants. RESULTS: During 4,007,477 person-years of follow-up, 2006 incident lung cancer cases were documented. Compared with participants without CVD, those …
Besides, polygenic risk scores were estimated by integrating genome-wide association studies identified risk variants. RESULTS: Durin …
Genomic landscape of non-small-cell lung cancer with methylthioadenosine phosphorylase (MTAP) deficiency.
Ashok Kumar P, Graziano SL, Danziger N, Pavlick D, Severson EA, Ramkissoon SH, Huang RSP, Decker B, Ross JS. Ashok Kumar P, et al. Cancer Med. 2023 Jan;12(2):1157-1166. doi: 10.1002/cam4.4971. Epub 2022 Jun 23. Cancer Med. 2023. PMID: 35747993 Free PMC article.
INTRODUCTION: New treatment strategies for advanced non-small-cell lung carcinoma (NSCLC) include synthetic lethality targets focused on protein arginine methyl transferases such as PRMT5 that exploit the impact of genomic loss of methylthioadenosine p …
INTRODUCTION: New treatment strategies for advanced non-small-cell lung carcinoma (NSCLC) include synthetic leth …
ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression.
Chuang TP, Lai WY, Gabre JL, Lind DE, Umapathy G, Bokhari AA, Bergman B, Kristenson L, Thorén FB, Le A, Doebele RC, Van den Eynden J, Palmer RH, Hallberg B. Chuang TP, et al. Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2216479120. doi: 10.1073/pnas.2216479120. Epub 2023 Feb 15. Proc Natl Acad Sci U S A. 2023. PMID: 36791109 Free PMC article.
Anaplastic lymphoma kinase (ALK) fusion variants in Non-Small Cell Lung Cancer (NSCLC) consist of numerous dimerizing fusion partners. Retrospective investigations suggest that treatment benefit in response to ALK tyrosine kinase inhibitors (TKIs) diff …
Anaplastic lymphoma kinase (ALK) fusion variants in Non-Small Cell Lung Cancer (NSCLC) consist of numerous dimer …
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer.
Pellini B, Madison RW, Childress MA, Miller ST, Gjoerup O, Cheng J, Huang RSP, Krainock M, Gupta P, Zou W, Shames DS, Moshkevich S, Ballinger M, Liu MC, Young A, Srivastava MK, Oxnard GR, Socinski MA. Pellini B, et al. Clin Cancer Res. 2023 Nov 14;29(22):4596-4605. doi: 10.1158/1078-0432.CCR-23-1578. Clin Cancer Res. 2023. PMID: 37702716 Free PMC article.
PURPOSE: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced driver-negative non-small cell lung cancer (NSCLC), with maintenance therapy given after induction. ...EXPERIMENTAL DESIGN: This retrospective study included 221 patients f …
PURPOSE: Chemoimmunotherapy (chemoIO) is a prevalent first-line treatment for advanced driver-negative non-small cell lung …
Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis.
Hata A, Nakajima T, Matsusaka K, Fukuyo M, Nakayama M, Morimoto J, Ito Y, Yamamoto T, Sakairi Y, Rahmutulla B, Ota S, Wada H, Suzuki H, Iwata T, Matsubara H, Ohara O, Yoshino I, Kaneda A. Hata A, et al. Int J Cancer. 2021 Jun 15;148(12):3008-3018. doi: 10.1002/ijc.33499. Epub 2021 Feb 19. Int J Cancer. 2021. PMID: 33533494 Free article.
Patients with idiopathic pulmonary fibrosis (IPF) are at higher risk of developing lung cancers including squamous cell lung carcinoma (SCC), which typically carries a poor prognosis. ...Here, we conducted targeted exon sequencing in SCCs with a …
Patients with idiopathic pulmonary fibrosis (IPF) are at higher risk of developing lung cancers including squamous cell …
TSC2 genetic variant and prognosis in non-small cell lung cancer after curative surgery.
Lee YH, Do SK, Lee SY, Kang HG, Choi JE, Hong MJ, Lee JH, Lee EB, Jeong JY, Shin KM, Lee WK, Seok Y, Cho S, Yoo SS, Lee J, Cha SI, Kim CH, Jheon S, Park JY. Lee YH, et al. Thorac Cancer. 2019 Feb;10(2):335-340. doi: 10.1111/1759-7714.12951. Epub 2018 Dec 26. Thorac Cancer. 2019. PMID: 30585697 Free PMC article.
Subgroup analysis showed that SNPs were significantly associated with survival outcomes in squamous cell carcinoma, ever-smokers, and stage I, but not in adenocarcinoma, never-smokers, and stage II-IIIA. The results suggest that TSC2 rs30259G > A may be us …
Subgroup analysis showed that SNPs were significantly associated with survival outcomes in squamous cell carcinoma, eve …
FGFR1-4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer.
Moes-Sosnowska J, Skupinska M, Lechowicz U, Szczepulska-Wojcik E, Skronska P, Rozy A, Stepniewska A, Langfort R, Rudzinski P, Orlowski T, Popiel D, Stanczak A, Wieczorek M, Chorostowska-Wynimko J. Moes-Sosnowska J, et al. Int J Mol Sci. 2022 Sep 10;23(18):10506. doi: 10.3390/ijms231810506. Int J Mol Sci. 2022. PMID: 36142417 Free PMC article.
While fibroblast growth factor receptors (FGFRs) are involved in several biological pathways and FGFR inhibitors may be useful in the treatment of squamous non-small cell lung cancer (Sq-NSCLC), FGFR aberrations are not well characterized in Sq-NSCLC. …
While fibroblast growth factor receptors (FGFRs) are involved in several biological pathways and FGFR inhibitors may be useful in the treatm …
Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW, Gao X, Zhang XC, Yang JJ, Chen ZH, Wu YL, Zhou Q. Wei XW, et al. Thorac Cancer. 2020 Jun;11(6):1512-1521. doi: 10.1111/1759-7714.13419. Epub 2020 Apr 14. Thorac Cancer. 2020. PMID: 32291971 Free PMC article.
BACKGROUND: Tyrosine kinase domain (TKD) mutation and particularly exon 20 insertion mutations of ERBB2 have been extensively reported in non-small cell lung cancer (NSCLC). Due to the increased accessibility of next-generation sequencing, more ERBB2 mutation …
BACKGROUND: Tyrosine kinase domain (TKD) mutation and particularly exon 20 insertion mutations of ERBB2 have been extensively reported in no …
ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W, Choi YL, Song JY, Zhu Y, Xu Q, Zhang F, Jiang L, Cheng J, Zheng G, Mao M. Zhao W, et al. Lung Cancer. 2016 Apr;94:22-7. doi: 10.1016/j.lungcan.2016.01.011. Epub 2016 Jan 21. Lung Cancer. 2016. PMID: 26973202
OBJECTIVES: Chromosomal rearrangements of ALK and ROS1 genes in non-small cell lung carcinoma (NSCLC) define a molecular subgroup of lung adenocarcinoma (ADC) that is amenable to targeted therapy with tyrosine kinase inhibitors (TKIs) crizotinib …
OBJECTIVES: Chromosomal rearrangements of ALK and ROS1 genes in non-small cell lung carcinoma (NSCLC) define a m …
207 results